Phase 1 tolerability and antiamoebic activity studies with 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go.10213): A new antiprotozoal agent

Go.10213 (new antiprotozoal) studied in volunteers for tolerance and in patients with intestinal Entamoeba histolytica for antiamebic activity, good results with only mild and transient side effects, may also be useful against other human protozoal diseases

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 1983-11, Vol.16 (5), p.517-522
Hauptverfasser:	Vaidya, A.B, Ray, D.K, Mankodi, N.A, Paul, T, Sheth, U.K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Antiprotozoal Agents - therapeutic use Biological and medical sciences Drug Evaluation drug toxicity Dysentery, Amebic - drug therapy Entamoeba histolytica Humans Male Medical sciences Middle Aged Nitroimidazoles - adverse effects Nitroimidazoles - therapeutic use Pharmacology. Drug treatments Treatment and control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Go.10213 (new antiprotozoal) studied in volunteers for tolerance and in patients with intestinal Entamoeba histolytica for antiamebic activity, good results with only mild and transient side effects, may also be useful against other human protozoal diseases
ISSN:	0306-5251 1365-2125
DOI:	10.1111/j.1365-2125.1983.tb02209.x